2 August 2024 - Drugs issued rare paediatric disease priority review vouchers that were redeemed had revenues that were similar to other brand drugs, according to recent research published in The Journal of Pediatrics.

The results suggest that “financial incentives for rare paediatric disease drug development may be solid and––in at least some cases––may exceed revenues from drugs treating more common conditions,” Ian Liu, of the division of pharmacoepidemiology and pharmacoeconomics at Brigham and Women’s Hospital, and colleagues wrote in their study.

Read RAPS article